Drug discovery and development remain inherently risky processes, with more than 90% of therapeutic candidates entering clinical testing ultimately failing to achieve regulatory approval.1 A significant proportion of these setbacks result from unforeseen safety concerns or insufficient therapeutic benefit in humans. These issues often stem from the limitations of traditional preclinical models, which do not fully replicate the complexity of human biology.
Animal models, in particular, frequently struggle to forecast clinical outcomes because differences in physiology, drug metabolism, immune function, and cellular behaviour between species can generate findings that do not translate to humans. As a result, researchers are increasingly seeking preclinical systems that more accurately reflect human biology.
Why human-relevant models are needed
Species-specific differences can affect several aspects of drug response, including:
- Drug metabolism and pharmacokinetics
- Immune system function
- Cellular signalling pathways
- Tissue structure and organ physiology
These differences contribute to a translational gap between preclinical findings and clinical outcomes, helping explain why so many drug candidates fail during development.1
Closing the translational gap with new approach methodologies
To address these challenges, the United States Congress enacted the FDA Modernization Act 2.0 in 2022, eliminating the longstanding requirement for animal testing as the sole means of evaluating a new drug's safety and effectiveness.2 The FDA can now consider evidence generated from qualified alternative platforms, including organoids, organ-on-chip technologies, advanced cell-based assays, and computational models.
Collectively known as new approach methodologies (NAMs), these technologies provide more representative models of human health and disease by capturing important features such as tissue architecture, cellular diversity, and molecular signalling networks.2
Organoids are transforming translational research
Among the various NAMs, organoids have emerged as particularly promising tools. Generated from human pluripotent stem cells, organoids are three-dimensional (3D), multicellular in vitro systems that reproduce many of the structural and functional characteristics of native human tissues.3
Because they reflect human-specific biological processes, organoids have become increasingly valuable for translational research and drug development.
However, achieving reliable and predictive results depends not only on the biological relevance of the model itself but also on the quality and consistency of the reagents used throughout the experimental workflow.
Risks associated with impure functional antibodies
Functional antibodies serve as critical research tools for modulating signalling pathways, activating immune cells, neutralising cytokines, and selectively depleting target cell populations.4 Researchers use these reagents extensively in organoid and animal models across oncology, neuroscience, immunology, and infectious disease research.
To produce accurate and reproducible findings, antibodies must be highly pure, specific, and consistent. This requirement is especially important in organoid studies, where sensitive cellular systems can respond to even trace levels of contaminants.
How contaminants can affect organoid studies
Common impurities include:
- Endotoxins
- Carrier proteins
- Preservatives
- Stabilisers
Even low levels of these contaminants may trigger cytokine release, inflammatory responses, or cellular stress, potentially altering organoid morphology, viability, and function. Off-target activity and cytotoxic artifacts can further compromise data quality, leading to inaccurate conclusions about a therapeutic candidate's safety or efficacy during screening studies in organoid and 3D bioprinted models.5
These concerns are amplified when working with patient-derived organoids, where limited sample availability makes experimental consistency particularly important.
High-purity functional antibodies support reliable organoid research
Because organoids are highly sensitive to environmental and experimental variables, selecting rigorously purified antibodies is essential for generating dependable and clinically relevant data. Bio X Cell offers ultrapure functional antibodies targeting both human and murine proteins that are optimised for organoid and organ-on-chip applications. These formulations contain minimal levels of endotoxins, preservatives, carrier proteins, and stabilisers, making them especially well-suited for sensitive patient-derived organoid systems.
The company's organoid-focused portfolio includes antibodies designed to modulate key signalling pathways relevant to immuno-oncology and autoimmune disease research, including anti-mouse and anti-human PD-1, anti-mouse and anti-human IFNγ, and anti-mouse 4-1BB antibodies.
Supporting experimental continuity across model systems
Maintaining consistency across model platforms is an important component of translational research. Using the same antibody formulation in both human organoid systems and xenograft or humanised mouse models can help reduce variability introduced by switching reagents between in vitro and in vivo studies.
Bio X Cell's portfolio of in vivo-ready antibodies supports this continuity, enabling researchers to use the same antibody across organoid and animal studies while maintaining a streamlined translational workflow.
Overall, Bio X Cell's functional antibodies for organoid applications help minimise contaminant-related artifacts while delivering consistent performance, supporting more predictive, reproducible, and translationally relevant research outcomes.
References
1. Yildirim Z, et al. Next-gen therapeutics: Pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. Annu Rev Pharmacol Toxicol. 2025;65:71-90.
2. Zushin PJH, et al. FDA Modernization Act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J Clin Invest. 2023;133(21):e175824.
3. Sinha A, et al. Organoid: Biomedical application, biobanking, and pathways to translation. Heliyon. 2025;11(10):e43028.
4. Daëron M. The function of antibodies. Immunol Rev. 2024;328(1):113-125.
5. Heinrich MA, et al. Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro models. Biomater Adv. 2023;144:213220.
This blog was inspired by Bio X Cell's original content.